AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020
August 06, 2020 07:01 ET
|
Amryt Pharma Plc
AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020 New revenue guidance of $170M - $175M in 2020 Conference call and webcast today 0830 ET / 1330 BST DUBLIN,...
AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE
July 29, 2020 07:00 ET
|
Amryt Pharma Plc
AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE Monday, August 3, 2020 at 1000 ET / 1500 BST DUBLIN, Ireland, and...
AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)
June 03, 2020 07:00 ET
|
Amryt Pharma Plc
June 3, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE...